The Union government has proposed tighter regulatory oversight of antimicrobial medicines to address the growing threat of antimicrobial resistance (AMR). The proposed move aims to strengthen quality, safety and efficacy checks before granting new manufacturing licences for these medicines.
Government Proposes Changes to Drug Regulations
The Ministry of Health and Family Welfare has proposed amendments to the New Drugs and Clinical Trials Rules, 2019, to bring antimicrobial medicines under stricter regulatory scrutiny.
Under the proposed changes, manufacturers will need to obtain prior permission from the Central Licensing Authority (CLA) before approaching state licensing authorities for manufacturing licences for antimicrobial products.
The government plans to include antimicrobial medicines in the definition of a ‘new drug’ under Rule 2(1)(w)(v) of the existing rules. This step will introduce an additional regulatory safeguard and strengthen oversight of antimicrobial drug manufacturing.
Existing Manufacturing Licences to Remain Valid
The proposed regulatory changes will apply prospectively. Therefore, manufacturers holding existing licences will not need to seek fresh approvals, and their current manufacturing licences will remain valid.
According to the Health Ministry, the move addresses concerns over antimicrobial manufacturing licences being granted without adequate regulatory assessments. These assessments include bioavailability and bioequivalence studies, as well as stability testing.
Focus on Tackling Antimicrobial Resistance
Antimicrobial resistance occurs when bacteria, viruses, fungi and parasites develop resistance to medicines designed to treat infections, making treatment more difficult.
Through the proposed amendments, the government aims to improve regulatory checks on antimicrobial medicines and ensure that manufacturers meet the required standards for quality, safety and efficacy.
However, industry experts have cautioned that the additional compliance requirements could increase costs for pharmaceutical manufacturers, particularly micro, small and medium enterprises (MSMEs). They have also raised concerns about the potential impact on the availability and affordability of antimicrobial medicines.
The proposed changes seek to strengthen India’s regulatory framework for antimicrobial medicines while addressing concerns surrounding drug resistance and ensuring appropriate scrutiny of new manufacturing licences, as reported by economictimes.indiatimes.com.



















